Therapiemonitoring beim metastasierten kastrationsresistenten Prostatakarzinom

Stefan Hinz

doi:10.1055/s-0043-117346

TumorDiagnostik & Therapie, Inhaltsverzeichnis

TumorDiagnostik & Therapie 2017; 38(09): 566-570
DOI: 10.1055/s-0043-117346

Thieme Onkologie aktuell

Therapiemonitoring beim metastasierten kastrationsresistenten Prostatakarzinom

Monitoring of treatment for metastatic castration-resistant prostate cancer

Stefan Hinz

Abstract

Zusammenfassung

Für die Behandlung des metastasierten kastrationsresistenten Prostatakarzinoms (mCRPC) stehen aktuell als Therapieoptionen Abirateronacetat, Enzalutamid, Docetaxel, Cabazitaxel und Radium-223 zur Verfügung, wobei die optimale Abfolge in der Therapiesequenz noch unklar ist. Es existieren auch noch keine verlässlichen prädiktiven Biomarker zur Vorhersage des Therapieansprechens und damit zur besseren Patientenselektion. Für das Gesamtüberleben ist entscheidend, dass jeder Patient möglichst alle verfügbaren Therapieoptionen erhält. Dies setzt ein frühzeitiges Erkennen einer Progression als Indikation für einen Therapiewechsel voraus. In diesem Zusammenhang ist die Durchführung eines strukturierten Therapiemonitorings im klinischen Alltag wichtig.

Abstract

Treatments currently available for metastatic castrationresistant prostate cancer (mCRPC) include abiraterone acetate, enzalutamide, docetaxel, cabazitaxel, and radium-223. However, the optimal sequence of these agents is still unclear, and markers to predict treatment response and facilitate patient selection remain an unmet need. In terms of overall survival, it is crucial that patients receive all treatment options currently available. This requires early detection of progression as an indication for a treatment switch. In this context, a structured monitoring of treatment is important in clinical practice.

Schlüsselwörter

Prostatakarzinom - Kastrationsresistenz - Biomarker - Therapiemonitoring - Abirateronacetat - Abirateron - Enzalutamid

Key words

prostate cancer - castration-resistant prostate cancer - biomarkers - treatment monitoring - abiraterone acetate - abiraterone - enzalutamide

Volltext

Referenzen

Literatur
1 Flaig TW. et al. Treatment evolution for metastatic castration-resistant prostate cancer (mCRPC) with recent introduction of new oral agents: Retrospective analysis of real world data. J Clin Oncol 2014; 32: (suppl; abstr) e16010
2 Sweeney C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 2014; 32: Abstract. LBA2
3 James ND. et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 2015; 33: (suppl; abstr). 5001
4 Parker C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213-223
5 De Bono JS. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154
6 Caffo O. et al. Activity of subsequent new drugs (NDs) in post-docetaxel (DOC) failure for metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A multicenter Italian experience. J Clin Oncol 2014; 32: (suppl; abstr) 5089
7 Loriot Y. et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013; 24: 1807-1812
8 Noonan KL. et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013; 24: 1802-1807
9 Schrader AJ. et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014; 65: 30-36
10 Zhang T. et al. Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2014; 32: (suppl; abstr) e16031
11 Antonarakis ES. et al. Androgen receptor splice variant, AR-V7, and resistance to enzalutamide and abiraterone in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2014; 32: (suppl; abstr) 5001
12 Antonarakis ES. et al. Splice variant 7 (AR-V7) and responses in men with metastatic castrataion-resistant prostate cancer. J Clin Oncol 2015; 33: (suppl 7, abstr). 138
13 Onstenk W. et al. Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells. Eur Urol 2015; 68: 939-945
14 Nakazawa M. et al. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol 2015; 26: 1859-1865
15 Todenhöfer T. et al. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastastic Castration Resistant Prostate Cancer. J Urol 2017; 197: 135-142
16 Takeuchi T. et al. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs of castration resistant prostate cancer. Res Rep Urol 2016; 8: 21-25
17 Bernemann C. et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Astration Resisatnt Prostate Cancer. Eur Urol 2017; 71: 1-3
18 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
19 Chen TW, Bedard PL. Personalized medicine for metastatic breast cancer. Current opinion in Oncology 2013; 25: 615-624
20 Dancey JE. et al. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res 2010; 16: 1745-1755
21 Scher HI. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159
22 Nelius T. et al. PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy. Prostate 2009; 69: 1802-1807
23 Lorente JA. et al. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 1348-1351
24 Boegemann M. et al. Dynamic changes of alkaline phosphatase as surrogate for best clinical benefit and overall survival during very early abiraterone therapy compared to PSA-changes in bone metastatic castration resistant prostate cancer. J Clin Oncol 2015; 33: (suppl 7; abstr) 260
25 Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2. https://clinicaltrials.gov/show/NCT01160705
26 Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy. https://clinicaltrials.gov/show/NCT02099864
27 Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy (PROMOTE). https://clinicaltrials.gov/show/NCT01953640
28 Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer. https://clinicaltrials.gov/show/NCT01576172
29 Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer (PREMIERE-SOGUG). https://clinicaltrials.gov/show/NCT02288936
30 de Bono JS. et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309
31 Goodman Jr OB. et al. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev 2009; 18: 1904-1913
32 Scher HI. et al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized, double-blind, placebo-controlled, phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011; 29: (suppl abstr) LBA4517
33 Eisenhauer EA. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
34 Ryan CJ. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138-148
35 Beer TM. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-433
36 Ryan CJ. et al. Association of radiographic progression-free survival (RPFS) adapted from Prostate Cancer Working Group 2 (PCWG2) consensus criteria (APCWG2) with overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): result from COU-AA-302. ESMO 2012; 89: (Abstract; oral presentation) 4O
37 Miller K. et al. Metastasiertes kastrationsresistentes Prostatakarzinom: Positionspapier für ein strukturiertes Therapiemonitoring. Urologe 2014; 53: 710-714
38 Lorente JA. et al. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer. J Urol 1996; 155: 1348-1351